IL141114A - Derivatives of carbapenem-3 carboxylic acids, their preparation and pharmaceutical preparations containing them - Google Patents

Derivatives of carbapenem-3 carboxylic acids, their preparation and pharmaceutical preparations containing them

Info

Publication number
IL141114A
IL141114A IL14111499A IL14111499A IL141114A IL 141114 A IL141114 A IL 141114A IL 14111499 A IL14111499 A IL 14111499A IL 14111499 A IL14111499 A IL 14111499A IL 141114 A IL141114 A IL 141114A
Authority
IL
Israel
Prior art keywords
heterocyclyl
methyl
compound
compounds
hydroxyethyl
Prior art date
Application number
IL14111499A
Other languages
English (en)
Hebrew (he)
Other versions
IL141114A0 (en
Original Assignee
Pfaendler Hans Rudolf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfaendler Hans Rudolf filed Critical Pfaendler Hans Rudolf
Publication of IL141114A0 publication Critical patent/IL141114A0/xx
Publication of IL141114A publication Critical patent/IL141114A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
IL14111499A 1998-07-28 1999-07-23 Derivatives of carbapenem-3 carboxylic acids, their preparation and pharmaceutical preparations containing them IL141114A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98114067A EP0976752A1 (en) 1998-07-28 1998-07-28 C-2 S/O- and S/N-Formaldehyde acetal derivatives of carbapenem antibiotics
PCT/EP1999/005295 WO2000006574A1 (en) 1998-07-28 1999-07-23 NOVEL C-2 S/O- AND S/N FORMALDEHYDE ACETAL DERIVATIVES OF CARBAPENEM-3-CARBOXYLIC ACIDS AND THEIR USE AS ANTIBIOTICS AND β-LACTAMASE INHIBITORS

Publications (2)

Publication Number Publication Date
IL141114A0 IL141114A0 (en) 2002-02-10
IL141114A true IL141114A (en) 2004-02-08

Family

ID=8232355

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14111499A IL141114A (en) 1998-07-28 1999-07-23 Derivatives of carbapenem-3 carboxylic acids, their preparation and pharmaceutical preparations containing them

Country Status (17)

Country Link
US (1) US6482818B2 (enExample)
EP (2) EP0976752A1 (enExample)
JP (1) JP4598273B2 (enExample)
KR (1) KR20010086351A (enExample)
CN (1) CN1154649C (enExample)
AT (1) ATE243696T1 (enExample)
AU (1) AU760249B2 (enExample)
CA (1) CA2338776C (enExample)
DE (1) DE69909098T2 (enExample)
ES (1) ES2203164T3 (enExample)
HU (1) HUP0102729A3 (enExample)
IL (1) IL141114A (enExample)
MX (1) MXPA01000905A (enExample)
NZ (1) NZ509578A (enExample)
PT (1) PT1100800E (enExample)
WO (1) WO2000006574A1 (enExample)
ZA (1) ZA200100737B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2576677A1 (en) * 2004-08-23 2006-03-02 Sicor, Inc. Synthesis of idarubin aglycone
JP5276653B2 (ja) 2007-05-21 2013-08-28 ハンス・ルドルフ・プフェンドラー カルバペネム類を含む殺菌性抗mrsa活性医薬組成物
CN101412718B (zh) * 2007-10-19 2011-04-27 山东轩竹医药科技有限公司 含有硫基杂环胺甲酰基的碳青霉烯衍生物
CN103059028B (zh) * 2013-01-30 2014-05-07 山东罗欣药业股份有限公司 一种替比培南匹伏酯的制备方法
CN114957258A (zh) * 2021-02-25 2022-08-30 华东理工大学 基于碳青霉烯结构的广谱丝氨酸β-内酰胺酶抑制剂的合成及其在耐药细菌抑制中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58116485A (ja) * 1981-12-29 1983-07-11 Shionogi & Co Ltd 新規抗生物質カルバペネム誘導体およびその製造法
GB2116540B (en) * 1981-11-10 1985-07-17 Shionogi & Co Pluracidomycin b c and d and analogs thereof their production and a microorganism for use therein
JPS58124785A (ja) * 1982-01-20 1983-07-25 Shionogi & Co Ltd プルラシドマイシンbおよびcのデオキシ体ならびにその製造法
JPS6054387A (ja) * 1983-08-03 1985-03-28 メルク エンド カムパニ− インコ−ポレ−テツド チエナマイシンの誘導体製造法
CA1285940C (en) * 1984-07-02 1991-07-09 Merck & Co., Inc. Carbapenems having a 2-quaternary heteroarylalkylthio substituent
IE851586L (en) * 1984-07-02 1986-01-02 Interchem Internat S A I methylcarbapenems having a 2-quaternary¹heteroarylalkylthio substituent
JPS63255283A (ja) * 1987-04-11 1988-10-21 Nippon Redarii Kk (1r,5s,6s)−2−〔(3−置換イミダゾリニウム−1−イル)アルキル〕チオ−6−〔(r)−1−ヒドロキシエチル〕−1−メチル−カルバペネム−3−カルボキシレ−ト
US5116833A (en) * 1990-10-19 1992-05-26 Bristol-Myers Squibb Company Antibiotic c-3 dithioacetal-substituted carbapenem compounds, compositions, and methods of use thereof

Also Published As

Publication number Publication date
HUP0102729A2 (hu) 2002-01-28
KR20010086351A (ko) 2001-09-10
JP4598273B2 (ja) 2010-12-15
PT1100800E (pt) 2003-11-28
AU5163999A (en) 2000-02-21
ZA200100737B (en) 2002-07-25
EP0976752A1 (en) 2000-02-02
CN1311790A (zh) 2001-09-05
EP1100800B1 (en) 2003-06-25
MXPA01000905A (es) 2002-06-04
AU760249B2 (en) 2003-05-08
EP1100800A1 (en) 2001-05-23
DE69909098D1 (de) 2003-07-31
CA2338776C (en) 2008-04-29
US20010031749A1 (en) 2001-10-18
NZ509578A (en) 2003-06-30
WO2000006574A1 (en) 2000-02-10
CN1154649C (zh) 2004-06-23
ES2203164T3 (es) 2004-04-01
IL141114A0 (en) 2002-02-10
HUP0102729A3 (en) 2002-09-30
CA2338776A1 (en) 2000-02-10
JP2002521484A (ja) 2002-07-16
ATE243696T1 (de) 2003-07-15
US6482818B2 (en) 2002-11-19
DE69909098T2 (de) 2004-04-08

Similar Documents

Publication Publication Date Title
FI84826C (fi) Foerfarande foer framstaellning av 6 -(1-hydroxietyl-2-substituerad-2-karbapenem-3-karboxylsyror anvaendbara som laekemedel.
IE46877B1 (en) Thienamycin derivatives
EP1100800B1 (en) Novel c-2 s/o- and s/n formaldehyde acetal derivatives of carbapenem-3-carboxylic acids and their use as antibiotics and beta-lactamase inhibitors
JPH0819135B2 (ja) 安定なオキサペネム‐3‐カルボン酸
AU609488B2 (en) (5r, 6s, 1r)-6-(1-hydroxyethyl)-2-(methoxymethyl)penem-3- carboxylic acid derivatives
JP2654201B2 (ja) 製薬学的調製物
US4840946A (en) Benzazolythio-carbapenem antibiotics
KR910009270B1 (ko) 카바펜엠 항생제의 제조방법
IE44433B1 (en) Substituted n-methylene derivatives of thienamycin
US4540580A (en) 2-[(1'R)-1'-Aminoalkyl]penems
GB1570986A (en) Derivatives of thienamycin and its isomers
CZ2001277A3 (cs) Nové C2 S/O- a S/N-formaldehydacetalové deriváty karbapenem-3-karboxylových kyselin a jejich použití jako antibiotik a inhibitorů Blaktamáz
JP2002521484A5 (enExample)
CS259892B2 (en) Method of 6-(1-hydroxyethyl)-7-oxo-1-azabiclo/3,2,o/hept-en-2-carboxyl acid's derivatives production
JPH05194528A (ja) 新規な1−オキサペネム−3−カルボン酸類及びそのβ−ラクタマーゼ阻害薬としての用途
US20040260084A1 (en) Novel c-3 s/o-and s/n formaldehe acetal derivatives of cephalosporins and their use as antibotics
MXPA03003280A (es) Composiciones farmaceuticas que contienen acidos de oxapenem-3-carboxilicos.
AU2002351821A1 (en) Novel C-3 S/O- and S/N formaldehe acetal derivatives of cephalosporins and their use as antibiotics
KR20030070011A (ko) 옥사페넴-3-카르복시산을 포함하는 제약학적 조성물

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees